Masakazu Matsushita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Masakazu Matsushita has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Naoto Tamura
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo
6 shared publications Ken Yamaji
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo
5 shared publications- Ken Yamaji
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine , Tokyo
5 shared publications Naoto Tamura
Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine
4 shared publications- Makio Kusaoi
Department of Internal Medicine and Rheumatology Juntendo University School of Medicine Tokyo Japan
3 shared publications Hirofumi Amano
Department of Internal Medicine and Rheumatology, Juntendo University Nerima Hospital , Tokyo
2 shared publications
Latest Publications
- 20 February 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (5) , 794-800
Clinical characteristics of giant cell arteritis with ocular involvement: A single-centre retrospective study
Objectives: To clarify the clinical characteristics of patients with ocular involvement in giant cell arteritis (GCA). Methods: This was an observational, single-centre, retrospective study of patients with GCA treated at Juntendo University Hospital between January 2012 and July 2023. The study involved 71 patients, including 21 with ocular involvement: 10 had fundus findings such as anterior ischemic optic neuropathy or central retinal artery occlusion (6 with permanent vision loss) and 11 without fundus findings. The demographic and clinical features of GCA were compared between patients with and without ocular involvement. Results: The temporal artery was found to be affected more frequently in cases with ocular involvement than in those without on positron emission tomography/computed tomography (P = .013) and vascular ultrasound (P = .02). The average number of signs and symptoms observed before diagnosis was higher in patients with ocular involvement than in those without (P < .001). The period from the appearance of ocular involvement to therapy initiation was shorter in patients with fundus findings than in those without (8.2 vs. 73.8 days; P = .032). Conclusions: Early imaging and early consultation with an ophthalmologist are important, as ocular involvement with fundus findings tended to occur earlier in GCA patients than without fundus findings.
- 20 February 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (5) , 794-800
Clinical characteristics of giant cell arteritis with ocular involvement: A single-centre retrospective study
Objectives: To clarify the clinical characteristics of patients with ocular involvement in giant cell arteritis (GCA). Methods: This was an observational, single-centre, retrospective study of patients with GCA treated at Juntendo University Hospital between January 2012 and July 2023. The study involved 71 patients, including 21 with ocular involvement: 10 had fundus findings such as anterior ischemic optic neuropathy or central retinal artery occlusion (6 with permanent vision loss) and 11 without fundus findings. The demographic and clinical features of GCA were compared between patients with and without ocular involvement. Results: The temporal artery was found to be affected more frequently in cases with ocular involvement than in those without on positron emission tomography/computed tomography (P = .013) and vascular ultrasound (P = .02). The average number of signs and symptoms observed before diagnosis was higher in patients with ocular involvement than in those without (P < .001). The period from the appearance of ocular involvement to therapy initiation was shorter in patients with fundus findings than in those without (8.2 vs. 73.8 days; P = .032). Conclusions: Early imaging and early consultation with an ophthalmologist are important, as ocular involvement with fundus findings tended to occur earlier in GCA patients than without fundus findings.
- 22 January 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (4) , 566-573
Developments in clinical practice treating systemic lupus erythematosus—A single-centre retrospective longitudinal study in Japan
Objectives: To assess treatment patterns for systemic lupus erythematosus from 2012 to 2024 and evaluate corresponding changes in serological activity and relapse rates. Methods: We retrospectively reviewed medical records of 1705 patients with systemic lupus erythematosus treated at a single centre between 2012 and 2024. Temporal trends in therapeutic approaches, glucocorticoid (GC) use, and clinical outcomes were analysed. Results: Use of GC monotherapy declined from 58.3% in 2012 to 22.4% in 2024. Combination therapies (GC and hydroxychloroquine, with or without immunosuppressants) increased from 1.0% in 2015 to 41.6% in 2024, while biologics use rose from 0.9% in 2018 to 12.5% in 2024. Quadruple therapy (GC, hydroxychloroquine, immunosuppressants, and biologics) also expanded from 0.4% in 2018 to 6.2% in 2024. The mean GC dose decreased from 7.7 mg/day in 2012 to 4.6 mg/day in 2024, and the median dose, stable at 5 mg/day for many years, declined to 4.6 mg in 2023 and 4.2 mg in 2024. The proportion of patients with elevated serological activity steadily decreased. Flare rates peaked at 8.1% in 2016 but stabilised at ~4% after 2020. Conclusions: These findings suggest that improved disease control can increasingly be achieved in real-world practice while reducing long-term GC dependence.
- 22 January 2026
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 36 (4) , 566-573
Developments in clinical practice treating systemic lupus erythematosus—A single-centre retrospective longitudinal study in Japan
Objectives: To assess treatment patterns for systemic lupus erythematosus from 2012 to 2024 and evaluate corresponding changes in serological activity and relapse rates. Methods: We retrospectively reviewed medical records of 1705 patients with systemic lupus erythematosus treated at a single centre between 2012 and 2024. Temporal trends in therapeutic approaches, glucocorticoid (GC) use, and clinical outcomes were analysed. Results: Use of GC monotherapy declined from 58.3% in 2012 to 22.4% in 2024. Combination therapies (GC and hydroxychloroquine, with or without immunosuppressants) increased from 1.0% in 2015 to 41.6% in 2024, while biologics use rose from 0.9% in 2018 to 12.5% in 2024. Quadruple therapy (GC, hydroxychloroquine, immunosuppressants, and biologics) also expanded from 0.4% in 2018 to 6.2% in 2024. The mean GC dose decreased from 7.7 mg/day in 2012 to 4.6 mg/day in 2024, and the median dose, stable at 5 mg/day for many years, declined to 4.6 mg in 2023 and 4.2 mg in 2024. The proportion of patients with elevated serological activity steadily decreased. Flare rates peaked at 8.1% in 2016 but stabilised at ~4% after 2020. Conclusions: These findings suggest that improved disease control can increasingly be achieved in real-world practice while reducing long-term GC dependence.
- 25 June 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (11) , 5776-5784
SLE-DAS remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in SLE remission and lupus low disease activity state
Objectives: The treat-to-target (T2T) approach for SLE has recently been proposed. However, the most suitable criterion for determining remission or low disease activity (LDA) using patient-reported outcomes (PROs) remains unknown. This study aimed to compare the relationship between PROs and various remission criteria, including the definition of remission in SLE (DORIS), SLE disease activity score (SLE-DAS) remission, lupus low disease activity state (LLDAS) and SLE-DAS LDA. Methods: A multicentre prospective study was conducted involving patients with SLE who visited Juntendo University and its affiliated hospitals between 2018 and 2024. A cross-sectional analysis was performed using surveys completed by physicians and patients. Multivariate analyses were performed to explore the relationship between PROs and remission/LDA criteria. Quality of life was evaluated using the medical outcomes study 36-item short-form health survey (SF-36) and EuroQol-5D. Results: This study included 334 patients. All remission and LDA criteria were significantly associated with the SF-36 physical component summary, with SLE-DAS remission demonstrating superior accuracy metrics compared with DORIS remission. No associations were observed with the mental component summary for any remission or LDA criteria. Regarding the EuroQol-5D, no correlations were identified with DORIS remission; however, correlations were observed with other remissions and LDA criteria. Conclusion: Remission and LDA criteria based on the safety of oestrogens in lupus erythematosus national assessment SLE disease activity index and SLE-DAS exhibited similar associations with PROs. SLE-DAS remission and LDA represent valid treatment targets in a T2T approach, comparable to DORIS remission and LLDAS in terms of PROs.
- 25 June 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (11) , 5776-5784
SLE-DAS remission and low disease activity were similarly associated with patient-reported outcomes compared with definition of remission in SLE remission and lupus low disease activity state
Objectives: The treat-to-target (T2T) approach for SLE has recently been proposed. However, the most suitable criterion for determining remission or low disease activity (LDA) using patient-reported outcomes (PROs) remains unknown. This study aimed to compare the relationship between PROs and various remission criteria, including the definition of remission in SLE (DORIS), SLE disease activity score (SLE-DAS) remission, lupus low disease activity state (LLDAS) and SLE-DAS LDA. Methods: A multicentre prospective study was conducted involving patients with SLE who visited Juntendo University and its affiliated hospitals between 2018 and 2024. A cross-sectional analysis was performed using surveys completed by physicians and patients. Multivariate analyses were performed to explore the relationship between PROs and remission/LDA criteria. Quality of life was evaluated using the medical outcomes study 36-item short-form health survey (SF-36) and EuroQol-5D. Results: This study included 334 patients. All remission and LDA criteria were significantly associated with the SF-36 physical component summary, with SLE-DAS remission demonstrating superior accuracy metrics compared with DORIS remission. No associations were observed with the mental component summary for any remission or LDA criteria. Regarding the EuroQol-5D, no correlations were identified with DORIS remission; however, correlations were observed with other remissions and LDA criteria. Conclusion: Remission and LDA criteria based on the safety of oestrogens in lupus erythematosus national assessment SLE disease activity index and SLE-DAS exhibited similar associations with PROs. SLE-DAS remission and LDA represent valid treatment targets in a T2T approach, comparable to DORIS remission and LLDAS in terms of PROs.
- 11 March 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 35 (5) , 850-858
Prevalence of systemic lupus erythematosus and age-stratified treatment trends in the Japanese population: A cross-sectional study based on the National Database of Health Insurance Claims
Objectives: The aim of this article is to investigate the prevalence of systemic lupus erythematosus (SLE) in Japan and explore its treatment regimens in different age groups. Methods: We identified patients with SLE from the National Database of Health Insurance Claims of anonymized health insurance-related information; they had disease names associated with SLE and were treated with glucocorticoids, hydroxychloroquine, or immunosuppressants. These data were used to investigate disease prevalence and profiles in Japan. Results: Of 74,277 patients with SLE, 12,816 were men (16.6%) and 61,961 were women (83.4%). Oral glucocorticoids were administered to 89.1% of patients and hydroxychloroquine to 21.4%. Regarding immunosuppressants, mycophenolate mofetil was prescribed for 49.2% of patients aged ≤14 years and tacrolimus for 35.5% of those aged 20–39 years; these rates were higher than those observed in other age groups. Conclusions: The high proportion of patients receiving treatment for comorbidities may be partially explained by the high rate of glucocorticoid use, as approval of hydroxychloroquine for the treatment of SLE was delayed in Japan. This is the first study to ascertain the prevalence of SLE and its treatment status in Japan using the National Database, thus providing useful basic data to improve the management of the disease.
- 11 March 2025
- Published by Oxford University Press (OUP) in Modern Rheumatology
- Vol. 35 (5) , 850-858
Prevalence of systemic lupus erythematosus and age-stratified treatment trends in the Japanese population: A cross-sectional study based on the National Database of Health Insurance Claims
Objectives: The aim of this article is to investigate the prevalence of systemic lupus erythematosus (SLE) in Japan and explore its treatment regimens in different age groups. Methods: We identified patients with SLE from the National Database of Health Insurance Claims of anonymized health insurance-related information; they had disease names associated with SLE and were treated with glucocorticoids, hydroxychloroquine, or immunosuppressants. These data were used to investigate disease prevalence and profiles in Japan. Results: Of 74,277 patients with SLE, 12,816 were men (16.6%) and 61,961 were women (83.4%). Oral glucocorticoids were administered to 89.1% of patients and hydroxychloroquine to 21.4%. Regarding immunosuppressants, mycophenolate mofetil was prescribed for 49.2% of patients aged ≤14 years and tacrolimus for 35.5% of those aged 20–39 years; these rates were higher than those observed in other age groups. Conclusions: The high proportion of patients receiving treatment for comorbidities may be partially explained by the high rate of glucocorticoid use, as approval of hydroxychloroquine for the treatment of SLE was delayed in Japan. This is the first study to ascertain the prevalence of SLE and its treatment status in Japan using the National Database, thus providing useful basic data to improve the management of the disease.
- Open Access
- 23 December 2023
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (1) , 167-175
Prognostic analysis of pulmonary hypertension with lung parenchymal lesion: Comparison of mortality with and without connective tissue disease
- 23 December 2023
- Published by Elsevier in Respiratory Investigation
- Vol. 62 (1) , 167-175
Open AccessPrognostic analysis of pulmonary hypertension with lung parenchymal lesion: Comparison of mortality with and without connective tissue disease
- 19 August 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (11) , 2021-2030
Promoting awareness of terminology related to unmet medical needs in context of rheumatic diseases in Japan: a systematic review for evaluating unmet medical needs
To optimize patient prognosis, patient needs, including unmet needs, should be adequately assessed. However, such needs are more challenging to report and, consequently, more likely to go unmet compared with the needs reported by physicians. We aimed to determine the appropriate direction of future research on unmet medical needs in rheumatic diseases in Japan by conducting a literature review. We searched PubMed and Web of Science using 23 terms linked to unmet medical needs for major rheumatic diseases in Japan. Further, we collected articles on health-related quality of life and investigated the scales used for assessment, as well as whether the terms “unmet needs” or “unmet medical needs” were used. We identified 949 papers on 10 diseases, including systemic lupus erythematosus, systemic sclerosis, dermatomyositis, juvenile idiopathic arthritis, adult-onset Still’s disease, antiphospholipid syndrome, mixed connective tissue disease, Takayasu arteritis, Sjögren’s syndrome, and Behçet’s disease; 25 of the 949 papers were selected for full-text review. Fifteen articles on five diseases were related to health-related quality of life. The term “unmet needs” was used in only one article. Six out of 15 studies used the 36-item short form survey, whereas the scales used in other studies differed. The optimal treatment plan determined by a physician may not necessarily align with the best interests of the patient. In clinical research, cross sectional and standardized indicators of health-related quality of life should be employed along with highly discretionary questionnaires to assess and optimize resource allocation in healthcare and simultaneously achieve patient-desired outcomes.
- 19 August 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (11) , 2021-2030
Promoting awareness of terminology related to unmet medical needs in context of rheumatic diseases in Japan: a systematic review for evaluating unmet medical needs
To optimize patient prognosis, patient needs, including unmet needs, should be adequately assessed. However, such needs are more challenging to report and, consequently, more likely to go unmet compared with the needs reported by physicians. We aimed to determine the appropriate direction of future research on unmet medical needs in rheumatic diseases in Japan by conducting a literature review. We searched PubMed and Web of Science using 23 terms linked to unmet medical needs for major rheumatic diseases in Japan. Further, we collected articles on health-related quality of life and investigated the scales used for assessment, as well as whether the terms “unmet needs” or “unmet medical needs” were used. We identified 949 papers on 10 diseases, including systemic lupus erythematosus, systemic sclerosis, dermatomyositis, juvenile idiopathic arthritis, adult-onset Still’s disease, antiphospholipid syndrome, mixed connective tissue disease, Takayasu arteritis, Sjögren’s syndrome, and Behçet’s disease; 25 of the 949 papers were selected for full-text review. Fifteen articles on five diseases were related to health-related quality of life. The term “unmet needs” was used in only one article. Six out of 15 studies used the 36-item short form survey, whereas the scales used in other studies differed. The optimal treatment plan determined by a physician may not necessarily align with the best interests of the patient. In clinical research, cross sectional and standardized indicators of health-related quality of life should be employed along with highly discretionary questionnaires to assess and optimize resource allocation in healthcare and simultaneously achieve patient-desired outcomes.
- Open Access
- 1 January 2020
- Published by The Jutendo Medical Journal in Juntendo Medical Journal
- Vol. 66 (1) , 21-26
Extra-articular Manifestations of Rheumatoid Arthritis
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2020
- Published by The Jutendo Medical Journal in Juntendo Medical Journal
- Vol. 66 (1) , 21-26
Open AccessExtra-articular Manifestations of Rheumatoid Arthritis
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- Open Access
- 11 September 2019
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 13 (1) , 1-5
Diagnosis of giant cell arteritis by head-contrast three-dimensional computed tomography angiography: two case reports
Introduction: Temporal artery biopsy is essential for the diagnosis of giant cell arteritis. It has been shown that 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance angiography, and ultrasonography are useful for the diagnosis of giant cell arteritis. However, there are only a few reports on the usefulness of three-dimensional computed tomography angiography in the diagnosis of giant cell arteritis. We describe two cases in which giant cell arteritis was difficult to diagnose using positron emission tomography-computed tomography and magnetic resonance angiography but was diagnosed using three-dimensional computed tomography angiography, thus showing the importance of three-dimensional computed tomography angiography in the diagnosis of giant cell arteritis. Case presentation: Case 1: An 81-year-old Japanese man. Laboratory investigations revealed normocytic anemia and raised inflammatory marker levels. Slight bleeding in the right posterior pole of his eyeball and leukoma of his left cornea were observed on fundus examination. Stenosis and stoppage of the temporal artery were detected on three-dimensional computed tomography angiography. A diagnosis of giant cell arteritis was made, and he was started on orally administered prednisolone. His headache and C-reactive protein levels improved. Four weeks after glucocorticoid steroid treatment, three-dimensional computed tomography angiography revealed improvement in stenosis and stoppage of temporal artery. Case 2: A 74-year-old Japanese woman. A dose of 20 mg of prednisolone was administered and her polymyalgia and polyarthritis improved; however, her headache and ear occlusion persisted. Although vasculitis was not detected on positron emission tomography-computed tomography, stenosis and stoppage of the temporal artery were detected on computed tomography angiography. She was diagnosed as having giant cell arteritis and started on orally administered prednisolone treatment (60 mg daily). Her headache and C-reactive protein levels improved. Four weeks after glucocorticoid treatment, three-dimensional computed tomography angiography showed improvement in stenosis and stoppage of temporal artery. Conclusions: In both patients with giant cell arteritis, three-dimensional computed tomography angiography revealed improvement in stenosis and stoppage of temporal artery after glucocorticoid treatment. We conclude that computed tomography angiography along with magnetic resonance angiography, positron emission tomography-computed tomography, and ultrasonography are important for the diagnosis of giant cell arteritis.
- 11 September 2019
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 13 (1) , 1-5
Open AccessDiagnosis of giant cell arteritis by head-contrast three-dimensional computed tomography angiography: two case reports
Introduction: Temporal artery biopsy is essential for the diagnosis of giant cell arteritis. It has been shown that 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance angiography, and ultrasonography are useful for the diagnosis of giant cell arteritis. However, there are only a few reports on the usefulness of three-dimensional computed tomography angiography in the diagnosis of giant cell arteritis. We describe two cases in which giant cell arteritis was difficult to diagnose using positron emission tomography-computed tomography and magnetic resonance angiography but was diagnosed using three-dimensional computed tomography angiography, thus showing the importance of three-dimensional computed tomography angiography in the diagnosis of giant cell arteritis. Case presentation: Case 1: An 81-year-old Japanese man. Laboratory investigations revealed normocytic anemia and raised inflammatory marker levels. Slight bleeding in the right posterior pole of his eyeball and leukoma of his left cornea were observed on fundus examination. Stenosis and stoppage of the temporal artery were detected on three-dimensional computed tomography angiography. A diagnosis of giant cell arteritis was made, and he was started on orally administered prednisolone. His headache and C-reactive protein levels improved. Four weeks after glucocorticoid steroid treatment, three-dimensional computed tomography angiography revealed improvement in stenosis and stoppage of temporal artery. Case 2: A 74-year-old Japanese woman. A dose of 20 mg of prednisolone was administered and her polymyalgia and polyarthritis improved; however, her headache and ear occlusion persisted. Although vasculitis was not detected on positron emission tomography-computed tomography, stenosis and stoppage of the temporal artery were detected on computed tomography angiography. She was diagnosed as having giant cell arteritis and started on orally administered prednisolone treatment (60 mg daily). Her headache and C-reactive protein levels improved. Four weeks after glucocorticoid treatment, three-dimensional computed tomography angiography showed improvement in stenosis and stoppage of temporal artery. Conclusions: In both patients with giant cell arteritis, three-dimensional computed tomography angiography revealed improvement in stenosis and stoppage of temporal artery after glucocorticoid treatment. We conclude that computed tomography angiography along with magnetic resonance angiography, positron emission tomography-computed tomography, and ultrasonography are important for the diagnosis of giant cell arteritis.
- Open Access
- 24 April 2018
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 46 (6) , 2486-2494
A case of ankylosing spondylitis with concurrent Takayasu arteritis
We herein report a case involving a 56-year-old man who had experienced neck and lower back pain since the age of 23 years. Ankylosing spondylitis (AS) was diagnosed at 41 years of age, and treatment with sulfasalazine was initiated. At 44 years of age, the patient developed respiratory distress on exertion and chest pain. Aortic regurgitation (AR) was diagnosed via echocardiography, and the patient presented to our hospital for close examination and treatment. Coronary computed tomography angiography revealed no lesions in the coronary artery; however, magnetic resonance angiography revealed stenotic lesions in the left common carotid artery and left subclavian artery. Based on the findings of a physical examination, fundus examination, and blood tests, the patient was diagnosed with AS with concurrent Takayasu arteritis (TA). Upon administration of steroids to alleviate inflammation caused by an autoimmune mechanism, the patient’s chest symptoms and inflammatory findings improved. AR was treated with aortic valve replacement and prosthetic blood vessel replacement, after which the patient progressed well. Intraoperative aortic biopsy revealed findings pathologically consistent with TA. Although AS with concurrent AR is well described, AS with concurrent TA, as in the present case, is rare.
- 24 April 2018
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 46 (6) , 2486-2494
Open AccessA case of ankylosing spondylitis with concurrent Takayasu arteritis
We herein report a case involving a 56-year-old man who had experienced neck and lower back pain since the age of 23 years. Ankylosing spondylitis (AS) was diagnosed at 41 years of age, and treatment with sulfasalazine was initiated. At 44 years of age, the patient developed respiratory distress on exertion and chest pain. Aortic regurgitation (AR) was diagnosed via echocardiography, and the patient presented to our hospital for close examination and treatment. Coronary computed tomography angiography revealed no lesions in the coronary artery; however, magnetic resonance angiography revealed stenotic lesions in the left common carotid artery and left subclavian artery. Based on the findings of a physical examination, fundus examination, and blood tests, the patient was diagnosed with AS with concurrent Takayasu arteritis (TA). Upon administration of steroids to alleviate inflammation caused by an autoimmune mechanism, the patient’s chest symptoms and inflammatory findings improved. AR was treated with aortic valve replacement and prosthetic blood vessel replacement, after which the patient progressed well. Intraoperative aortic biopsy revealed findings pathologically consistent with TA. Although AS with concurrent AR is well described, AS with concurrent TA, as in the present case, is rare.